Revisiting the role of dose intensity in hematological malignancies

Experimental Hematology

Volumn 34, Issue 7, 2006, Pages 811-825

  Holmberg, Leona A ^a   Stewart, F Marc ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTIINFECTIVE AGENT; BLEOMYCIN; BORTEZOMIB; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; DACARBAZINE; DAUNORUBICIN; DIAZIQUONE; DOXORUBICIN; ERYTHROPOIETIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERFERON; LENALIDOMIDE; MELPHALAN; METHOTREXATE; MITOXANTRONE; PREDNISONE; PROCARBAZINE; RITUXIMAB; STEROID; THALIDOMIDE; UNINDEXED DRUG; VINBLASTINE; VINBLASTINE SULFATE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOTRANSPLANTATION; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL RESEARCH; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG MEGADOSE; DRUG SAFETY; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL; HODGKIN DISEASE; HUMAN; LEUKEMIA REMISSION; MALIGNANT NEOPLASTIC DISEASE; MULTIMODALITY CANCER THERAPY; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; STEM CELL MOBILIZATION; TREATMENT FAILURE; TREATMENT OUTCOME;

DOSE-RESPONSE RELATIONSHIP, DRUG; HEMATOLOGIC NEOPLASMS; HUMANS; STEM CELL TRANSPLANTATION;

EID: 33745206309     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2006.04.014     Document Type: Review

References (81)

1. DeVita Jr. V.T., Hellman S., and Rosenberg S.A. Important Advances in Oncology (1990), Lippincott Williams & Wilkins, Philadelphia p. 43-64
2. Schabel Jr. F.M., Griswold Jr. D.P., Corbett T.H., and Laster Jr. W.R. Increasing the therapeutic response rates to anticancer drugs by applying the basic principles of pharmacology. Cancer 54 6 Suppl (1984) 1160-1167
3. Hryniuk W.M. Average relative dose intensity and the impact on design of clinical trials. Semin Oncol 14 1 (1987) 65-74
4. Hryniuk W., and Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2 (1984) 1281-1288
5. Mayer R.J., Davis R.B., Schiffer C.A., et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 331 (1994) 896-903
6. Weick J.K., Kopecky K.J., Appelbaum F.R., et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 88 (1996) 2841-2851
7. Bloomfield C.D., Lawrence D., Byrd J.C., et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 58 (1998) 4173-4179
8. Byrd J.C., Dodge R.K., Carroll A., et al. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol 17 (1999) 3767-3775
9. Byrd J.C., Ruppert A.S., Mrozek K., et al. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13Q22) or t(16;16)(p13;q22): results form CALGB 8461. J Clin Oncol 22 (2004) 1087-1094
10. Witz F., Sadoun A., Perrin M.C., et al. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood 91 (1998) 2722-2730
11. Lowenberg B., Suciu S., Archimbaud E., et al. Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group. Blood 90 (1997) 2952-2961
12. Lowenberg B., van Putten W., Theobald M., et al. Dutch-Belgian Hemato-Oncology Cooperative Group; Swiss Group for Clinical Cancer Research. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 349 (2003) 743-752
13. Zittoun R.A., Mandelli F., Willemze R., et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 332 (1995) 217-223
14. Burnett A.K., Goldstone A.H., Stevens R.M., et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet 351 (1998) 700-708
15. Cassileth P.A., Harrington D.P., Appelbaum F.R., et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 339 (1998 Dec 3) 1649-1656
16. Harousseau J.L., Cahn J.Y., Pignon B., et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. Blood 90 (1990) 2978-2986
17. Ganser A., Krauter J., Hoeltzer D., et al. Late consolidation for patients with standard risk AML up to 60 years: results of a prospective randomized comparison of high dose ARAC and autologous PBSCT. Blood 104 (2004) 45a (abstract #145)
18. Krauter J., Heil G., Hoelzer D., et al. Treatment of adult patients with high risk acute myeloblastic leukemia up to age 60 years: role of consolidation therapy within a prospective multicenter trial. Blood 104 (2004) 179a (abstract #618)
19. Farag S., Ruppert A., Mrozek K., et al. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karotype: Cancer and Leukemia group B study. J Clin Oncol (2004) Nov 8 epub
20. Suciu S., Mandelli F., de Witte T., et al. EORTC and GIMEMA Leukemia Groups. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 102 (2003) 1232-1240
21. Burnett A.K., Wheatley K., Goldstone A.H., et al. Medical Research Council Adult and Paediatric Working Parties. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 118 (2002) 385-400
22. Horowitz M.M. Report on the state of the art in blood and bone marrow transplantation-the IBMTR/ABMTR summary slides with guide. IBMTR/ABMTR Newsletter 9 (2002) 1-11
23. Fung H.C., Stein A., Slovak M., et al. A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome. Biol Blood Marrow Transplant 9 (2003) 766-771
24. Bensinger W.I., Martin P.J., Storer B., et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 344 (2001) 175-181
25. Hsu K.C., Taylor C.A., O'Reilly R.A., et al. AML patients lacking kir ligand for donor KIR exhibit increased overall survival in HLA-identical sibling transplants. Biol Blood Marrow Transplant 10 (2004) 7
26. Cook M.A., Milligan D.W., Fegan C.D., et al. The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia. Blood 103 (2004) 1521-1526
27. Radich J.P., Gooley T., Bensinger W., et al. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood 102 (2003) 31-35
28. Diehl V., Franklin J., Pfreundschuh M., et al. German Hodgkin's Lymphoma Study Group. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348 (2003) 2386-2395
29. Diehl V, Stein H, Hummel M, Zollinger R, Connors JM. Hodgkin's lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. ASH Education Program Book. 2003:225-247.
30. Raemaekers J., Burgers M., Henry-Amar M., et al. Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy: interim results from the ongoing EORTC-LCG and GPMC phase III trial. The EORTC Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie. Ann Oncol 8 Suppl 1 (1997) 111-114
31. Federico M., Bellei M., Brice P., et al. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. J Clin Oncol 21 (2003) 2320-2325
32. Schmitz N., Pfistner B., Sextro M., et al. German Hodgkin's Lymphoma Study Group; Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 359 (2002) 2065-2071
33. Lazarus H.M., Rowlings P.A., Zhang M.J., et al. Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 17 (1999) 534-545
34. Constans M., Sureda A., Terol M.J., et al. Autologous stem cell transplantation for primary refractory Hodgkin's disease: results and clinical variables affecting outcome. Ann Oncol 14 (2003) 745-751
35. Sweetenham J.W., Carella A.M., Taghipour G., et al. High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party. J Clin Oncol 17 (1999) 3101-3109
36. Anderson J.E., Litzow M.R., Appelbaum F.R., et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience. J Clin Oncol 11 (1993) 2342-2350
37. Sureda A., and Schmitz N. Role of allogeneic stem cell transplantation in relapsed or refractory Hodgkin's disease. Ann Oncol 13 Suppl 1 (2002) 128-132
38. Lenz G., Dreyling M., Schiegnitz E., et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 104 (2004) 2667-2674
39. Ladetto M., Corradini P., Vallet S., et al. High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Blood 100 (2002) 1559-1565
40. Schouten H.C., Qian W., Kvaloy S., et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: Results from the randomized European CUP trial. J Clin Oncol 21 (2003) 3918-3927
41. Dreyling M., Lenz G., Schiegnitz E., et al. Early consolidation with myeloablative radio chemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle cell lymphoma-long term follow up of a prospective randomized trial of the European MCl network. Blood 104 (2004) 6a (abstract #7)
42. Blayney D.W., LeBlanc M.L., Grogan T., et al. Southwest Oncology Group. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). J Clin Oncol 21 (2003) 2466-2473
43. Tilly H., Lepage E., Coiffier B., et al. Groupe d'Etude des Lymphomes de l'Adulte. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 102 (2003) 4284-4289
44. Pfreundschuh M., Trumper L., Kloess M., et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of DSHNHL. Blood 104 (2004) 634-641
45. Pfreundschuh M., Trumper L., Kloess M., et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 104 (2004) 1584-1585
46. Verdonck L.F., von Imhoff G.W., Raemaheus J.M.M., et al. Six courses of intensified CHOP plus G-CSF compared to eight courses of standard CHOP in patients with intermediate-risk aggressive non-Hodgkin's lymphoma. Blood 106 (2005) 9a (abstract 14)
47. Sonneveld P., van Putten W., Holte H., et al. Intensified CHOP with Rituximab for intermediate or high-risk non-Hodgkin's lymphoma: Interim analysis of a randomized phase III trial in elderly patients by the Dutch Hovon and Nordic Lymphoma Groups. Blood 106 (2005) 10a (abstract 16)
48. Philip T., Chauvin F., Armitage J., et al. Parma international protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation. Blood 77 (1991) 1587-1592
49. Philip T., Guglielmi C., Hagenbeek A., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333 (1995) 1540-1545
50. Gianni A.M., Bregni M., Siena S., et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 336 (1997) 1290-1297
51. Haioun C., Lepage E., Gisselbrecht C., et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol-a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol 18 (2000) 3025-3030
52. Santini G., Salvagno L., Leoni P., et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol 16 (1998) 2796-2802
53. Kluin-Nelemans H.C., Zagonel V., Anastasopoulou A., et al. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study. J Natl Cancer Inst 93 (2001) 22-30
54. Milpied N., Deconinck E., Gaillard F., et al. Groupe Ouest-Est des Leucemies et des Autres Maladies du Sang. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 350 (2004) 1287-1295
55. Sweetenham J.W., Santini G., Qian W., et al. High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group. J Clin Oncol 19 (2001) 2927-2936
56. Magrath I., Adde M., Shad A., et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 14 (1996) 925-934
57. Schwenn M.R., Blattner S.R., Lynch E., and Weinstein H.J. HiC-COM: a 2-month intensive chemotherapy regimen for children with stage III and IV Burkitt's lymphoma and B-cell acute lymphoblastic leukemia. J Clin Oncol 9 (1991) 133-138
58. Sweetenham J.W., Pearce R., Taghipour G., Blaise D., Gisselbrecht C., and Goldstone A.H. Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma-outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation. J Clin Oncol 14 (1996) 2465-2472
59. van Besien K., Fausto R., Loberiza Jr. F.R., et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 102 (2003) 3521-3529
60. Levine J.E., Harris R.E., Loberiza Jr. F.R., et al. Lymphoma Study Writing Committee, International Bone Marrow Transplant Registry and Autologous Blood and Marrow Transplant Registry. A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood 101 (2003) 2476-2482
61. Escalon M.P., Champlin R.E., Saliba R.M., et al. Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol 22 (2004) 2419-2423
62. Maris M., Sandmaier B., Storer B., et al. Allogeneic hematopoeitc cell transplantation after fludarabine and 2 Gy total body radiation for relapsed and refractory mantle cell lymphoma. Blood 104 (2004) 231a (abstract #809)
63. 2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 99 (2002) 731-735
64. 2) in multiple myeloma patients. Blood 100 suppl 1 (2002) 431 (abstract 1669)
65. Attal M., Harousseau J.L., Stoppa A.M., et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335 (1996) 91-97
66. Child J.A., Morgan G.J., Davies F.E., et al. Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348 (2003) 1875-1883
67. Blade J., Sureda J.M., Ribera J., et al. High-dose therapy autotransplantation intensification versus continued conventional chemotherapy in multiple myeloma patients responding to initial chemotherapy: results of a prospective randomized trial from the Spanish Cooperative Group PETHEMA. Hematol J 4 (2003) S56
68. Barlogie B., Jagannath S., Vesole D.H., et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 89 (1997) 789-793
69. Lenhoff S., Hjorth M., Holmberg E., et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood 95 (2000) 7-11
70. Attal M., Harousseau J.L., Stoppa A.M., et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335 (1996) 91-97
71. Child J.A., Morgan G.J., Davies F.E., et al. Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348 (2003) 1875-1883
72. Sonneveld P., van der Holt B., Segeren C.M., et al. Intensive versus double intensive therapy in untreated multiple myeloma: updated analysis of the prospective phase III study HOVON 24 MM (Dutch-Belgian Haematology-Oncology Cooperative Group; The Netherlands). Hematol J 4 (2003) S59
73. Barlogie B., Jacobson J., Anderson K., Greipp P., Kyle R., and Crowley J. High-dose therapy versus conventional chemotherapy for newly diagnosed multiple myeloma: historical comparison of total therapy I versus standard SWOG trials and US Intergroup trial SWOG 9321. Hematol J 4 (2003) S57
74. Barlogie B., Shaughnessy J., Tricot G., et al. Treatment of multiple myeloma. Blood 103 (2004) 20-32
75. + cells to support single or tandem high-dose chemotherapy. Blood 95 (2000) 2234-2239
76. Attal M., Harousseau J.L., Facon T., et al. InterGroupe Francophone du Myelome. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349 (2003) 2495-2502
77. Cavo M., Cellini C., Zamagni E., et al. Superiority of double over single autologous stem cell transplantation as first-line therapy for multiple myeloma. Blood 104 (2004) 155a (abstract #536)
78. Einsele H., Liebisch P., Bargou R., et al. Single high-dose chemoradiotherapy versus tandem high-dose melphalan followed by auto-SCT for advanced multiple myeloma preliminary analysis. Blood 104 (2004) 156a (abstract 537)
79. Attal M., Harousseau J.-L., Leyvraz S., et al. Maintenance treatment with thalidomide after autologous transplantation for myeloma: first analysis of a prospective randomized study of the Intergroupe Francophone du Myelom (IIFM 99 02). Blood 104 (2004) 155a (abstract #535)
80. Barlogie B., Kyle R., Anderson K., et al. Comparable survival in multiple myeloma (MM) with high dose therapy (HDT) employing MEL 140 mg/m2 + TBI 12GY autotransplants versus standard dose therapy with VBMCP and no benefit from interferon (IFN) maintenance: results of intergroup trial S9321. Blood 102 (2003) 42a
81. Maloney D.G., Molina A.J., Sahebi F., et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 102 (2003) 3447-3454